Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

The molecular basis of the anticancer effect of statins

Open access

Published version of a preprint

Abstract

Statins, widely used cardiovascular drugs that lower cholesterol by inhibiting HMG-CoA reductase, have been increasingly recognized for their potential anticancer properties. This study elucidates the underlying mechanism, revealing that statins exploit Synthetic Lethality, a principle where the co-occurrence of two non-lethal events leads to cell death. Our computational analysis of approximately 37,000 SL pairs identified statins as potential drugs targeting genes involved in SL pairs with metastatic genes. In vitro validation on various cancer cell lines confirmed the anticancer efficacy of statins. This data-driven drug repurposing strategy provides a molecular basis for the anticancer effects of statins, offering translational opportunities in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-024-71240-6

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 (a) Cumulative distribution curve of the three scores extracted for all possible drugs independently; lines represent the drug score (red), the SL score (green), and the gene score (blue). An 80% threshold has been set to identify the initial minimum significant threshold of scores for candidate filtering, according to Pareto principle. By intersecting the curves and the 80% cutoff, preliminary thresholds were identified at DScore > 0.3, SLScore > 0.2, GScore > 0.1 (b) Probability distribution curves for the three scores are delineated; lines signify the drug score (red), the SL score (green), and the gene score (blue). The probability distribution of scores is a tool in statistics and data analysis, offering valuable insights into variable understanding, hypothesis testing, and outcome prediction. The area under the probability density function curve between two points corresponds to the probability that the variable falls within that interval of score. The score corresponding to the first notable peak beyond the minimum threshold, determined by the individual score corresponding to a cumulative percent greater than 80%, is chosen for each score. Consequently, the final thresholds were determined to be DScore > 0.35, SLScore > 0.5, and GScore > 0.35.
Fig. 1 (a) Cumulative distribution curve of the three scores extracted for all possible drugs independently; lines represent the drug score (red), the SL score (green), and the gene score (blue). An 80% threshold has been set to identify the initial minimum significant threshold of scores for candidate filtering, according to Pareto principle. By intersecting the curves and the 80% cutoff, preliminary thresholds were identified at DScore > 0.3, SLScore > 0.2, GScore > 0.1 (b) Probability distribution curves for the three scores are delineated; lines signify the drug score (red), the SL score (green), and the gene score (blue). The probability distribution of scores is a tool in statistics and data analysis, offering valuable insights into variable understanding, hypothesis testing, and outcome prediction. The area under the probability density function curve between two points corresponds to the probability that the variable falls within that interval of score. The score corresponding to the first notable peak beyond the minimum threshold, determined by the individual score corresponding to a cumulative percent greater than 80%, is chosen for each score. Consequently, the final thresholds were determined to be DScore > 0.35, SLScore > 0.5, and GScore > 0.35.CC BY · PubMed Central
Fig. 2 Graphical scheme of the three stages of our research approach: (i) Data Collection and Processing: Three types of entities (genes, drugs, and cancer types) are gathered and scrutinized from databases to explore the landscape of anti-metastatic repurposable drugs via SL. The dataset encompasses five types of relationships (metastatic gene, SL gene pair, drug–gene relationship, relationships between drugs and their approved indications, and synergistic drug combination), providing the computational groundwork for drug repositioning. (ii) Data Filtering: The dataset is sorted based on GScore, DScore, and SLScore values. The most promising candidates are pinpointed through cumulative percentages and alignment with the density distribution. Optimal scores are identified as GScore > 0.35, SLScore > 0.5, and DScore > 0.35. Within the pool of best candidates, a focused search was conducted to identify those with repurposable potential. (iii) Identification and Validation: Among the best repurposable candidates, statins have demonstrated antitumor activity in accordance with retrospective meta-analyses. The in vitro experimental validation is carried out with cell lines presenting necessary mutations for susceptibility and wild type cell lines as a negative control.
Fig. 2 Graphical scheme of the three stages of our research approach: (i) Data Collection and Processing: Three types of entities (genes, drugs, and cancer types) are gathered and scrutinized from databases to explore the landscape of anti-metastatic repurposable drugs via SL. The dataset encompasses five types of relationships (metastatic gene, SL gene pair, drug–gene relationship, relationships between drugs and their approved indications, and synergistic drug combination), providing the computational groundwork for drug repositioning. (ii) Data Filtering: The dataset is sorted based on GScore, DScore, and SLScore values. The most promising candidates are pinpointed through cumulative percentages and alignment with the density distribution. Optimal scores are identified as GScore > 0.35, SLScore > 0.5, and DScore > 0.35. Within the pool of best candidates, a focused search was conducted to identify those with repurposable potential. (iii) Identification and Validation: Among the best repurposable candidates, statins have demonstrated antitumor activity in accordance with retrospective meta-analyses. The in vitro experimental validation is carried out with cell lines presenting necessary mutations for susceptibility and wild type cell lines as a negative control.CC BY · PubMed Central
Fig. 3 Collection and processing of candidates to identify the repurposable drugs usable for the anticancer Synthetic Lethality approach. (a) The three-dimensional representation provides insight into the targeting of non-mutated genes in a Synthetic Lethality association with a deleted metastatic gene. The green triangles signify all the discerned drugs that target non-deleted genes in an SL pair with deleted metastatic genes, and are non-chemotherapeutic, totaling 1888. Among these, 230 candidates are repurposable (red dot). (b) The pie chart provides a visual representation of the distribution of the 1888 drugs we identified, grouped according to their status. Specifically, 44.8% of these drugs are already approved for cancer treatment, 43.0% are in clinical trial phase, while 12.2% encompass commercially available drugs that are used for non-cancer related treatments but have potential for repurposing in cancer therapy.
Fig. 3 Collection and processing of candidates to identify the repurposable drugs usable for the anticancer Synthetic Lethality approach. (a) The three-dimensional representation provides insight into the targeting of non-mutated genes in a Synthetic Lethality association with a deleted metastatic gene. The green triangles signify all the discerned drugs that target non-deleted genes in an SL pair with deleted metastatic genes, and are non-chemotherapeutic, totaling 1888. Among these, 230 candidates are repurposable (red dot). (b) The pie chart provides a visual representation of the distribution of the 1888 drugs we identified, grouped according to their status. Specifically, 44.8% of these drugs are already approved for cancer treatment, 43.0% are in clinical trial phase, while 12.2% encompass commercially available drugs that are used for non-cancer related treatments but have potential for repurposing in cancer therapy.CC BY · PubMed Central
Fig. 4 Graphical description of the filtering process applied during the identification of best candidates. (a) Through the implementation of statistically determined scoring thresholds (DScore > 0.35, SLScore > 0.5, GScore > 0.35), we have identified a subset of candidates exhibiting superior promise. This has resulted in a pool of 219 best candidates, represented by blue triangles. Within this pool, the number of repurposable drugs is further refined to 97, distinctly visualized as red dots. (b) Among the 219 best candidates, 55.7% have already received approval for use in cancer treatment, while 44.3% are commercially available drugs currently used for non-cancer treatments but show potential for repurposing in cancer therapy.
Fig. 4 Graphical description of the filtering process applied during the identification of best candidates. (a) Through the implementation of statistically determined scoring thresholds (DScore > 0.35, SLScore > 0.5, GScore > 0.35), we have identified a subset of candidates exhibiting superior promise. This has resulted in a pool of 219 best candidates, represented by blue triangles. Within this pool, the number of repurposable drugs is further refined to 97, distinctly visualized as red dots. (b) Among the 219 best candidates, 55.7% have already received approval for use in cancer treatment, while 44.3% are commercially available drugs currently used for non-cancer treatments but show potential for repurposing in cancer therapy.CC BY · PubMed Central
Fig. 5 Validation of the Synthetic Lethality hypothesis with Simvastatin. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Simvastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 2.108 µM, R2 = 0.9554. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 20.94 µM, R2 = 0.8715. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8 µM, R2 = 0.8427. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Simvastatin, remains unaffected across all tested Simvastatin concentrations.
Fig. 5 Validation of the Synthetic Lethality hypothesis with Simvastatin. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Simvastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 2.108 µM, R2 = 0.9554. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 20.94 µM, R2 = 0.8715. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8 µM, R2 = 0.8427. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Simvastatin, remains unaffected across all tested Simvastatin concentrations.CC BY · PubMed Central
Fig. 6 Lovastatin validation of the Synthetic Lethality hypothesis. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Lovastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 9.5 nM, R2 = 0.8. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8.7 µM, R2 = 0.82. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 522 nM, R2 = 0.78. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Lovastain, remains unaffected across all tested Lovastatin concentrations.
Fig. 6 Lovastatin validation of the Synthetic Lethality hypothesis. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Lovastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 9.5 nM, R2 = 0.8. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8.7 µM, R2 = 0.82. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 522 nM, R2 = 0.78. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Lovastain, remains unaffected across all tested Lovastatin concentrations.CC BY · PubMed Central
Fig. 7 Simvastatin and Lovastatin, selected from our data-driven analysis and substantiated by retrospective meta-analyses and extensive current prescriptions data, have demonstrated their antitumor activity rooted in Synthetic Lethality through experimental validation. This compelling evidence irrefutably establishes its therapeutic principle of statins, marking a significant stride in the realm of personalized medicine based on data-driven repurposed drugs.
Fig. 7 Simvastatin and Lovastatin, selected from our data-driven analysis and substantiated by retrospective meta-analyses and extensive current prescriptions data, have demonstrated their antitumor activity rooted in Synthetic Lethality through experimental validation. This compelling evidence irrefutably establishes its therapeutic principle of statins, marking a significant stride in the realm of personalized medicine based on data-driven repurposed drugs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 13

Metadata

Authors
Buccioli, G., Testa, C., Jacchetti, E., Pinoli, P., Carelli, S., Ceri, S., & Raimondi, M. T.
Affiliations
  • Politecnico di Milano (IT)
  • Fondazione Politecnico di Milano (IT)
  • Ospedale dei Bambini Vittore Buzzi (IT)
Corresponding author
  • Ceri, Stefano
  • Raimondi, Manuela T.
Venue
Scientific Reports
Published
2024-08-31
Volume
14
Issue
1
Pages
20298-20298
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4402087495
Cited by
13
References
59
Citations by year
2026: 5 · 2025: 8
FWCI
2.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Virtual Community of Pathological Anatomy (University of Castilla La Mancha) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
HORIZON EUROPE European Research Council (101053122)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
statins, anticancer effects, synthetic lethality, HMG-CoA reductase inhibition, drug repurposing, metastasis-associated genes, cancer cell lines, cholesterol-lowering drugs
MeSH terms
Antineoplastic Agents, Cell Survival, Computer Simulation, HeLa Cells, Humans, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cell Line, Tumor, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The molecular basis of the anticancer effect of statins. https://app.cochat.ai/papers/10.1038/s41598-024-71240-6
The paper
Buccioli, G., Testa, C., Jacchetti, E., Pinoli, P., Carelli, S., Ceri, S., & Raimondi, M. T. (2024). The molecular basis of the anticancer effect of statins. Scientific Reports. https://doi.org/10.1038/s41598-024-71240-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.